TheraRadar
Landscape / CNS
Data updated: Jun 28, 2026

OCD Clinical Trial Landscape

OCD is being studied across 84 clinical trials registered since 2008, with 27 programs currently active. The competitive pipeline includes 2 active Phase 3 trials, 15 active Phase 2 trials, and 7 active Phase 1 trials.

Top industry sponsors include Vericel Corporation, Biohaven Pharmaceuticals, Inc..

Trial activity

27 active / 84 total since 2008
Active by phase 2 Ph3 / 11 15 Ph2 / 46 7 Ph1 / 12 3 Ph4 / 15

Sponsor activity

Who is running trials now — green active, blue completed, red failed/terminated.

Sorted by active Active Done Failed
Vericel Corporation 1 0 0
Biohaven Pharmaceuticals, Inc. 0 3 0

How the field has grown

New-trial starts peaked in 2022 (8 registered); 2025 saw 5. The right-hand chart shows median Phase 3 enrollment by start year — the number in parentheses is that year's Phase 3 trial count (6 in total), so single-trial years (and years with no Phase 3 starts) are obvious. Both are by trial start date; the current year is partial.

New trials started by year

2016
4
2017
4
2018
6
2019
3
2020
4
2021
3
2022
8
2023
3
2024
5
2025
5
2026
4

TheraRadar.com

Median Phase 3 enrollment by start year

2016 (0)
0
2017 (1)
426
2018 (2)
33
2019 (0)
0
2020 (1)
456
2021 (1)
589
2022 (1)
50
2023 (0)
0
2024 (0)
0
2025 (0)
0
2026 (0)
0

TheraRadar.com

Full trial pipeline

Every active and completed trial across Phase 1–4, with enrollment analytics. Sortable, filterable, exportable with Pro.

NCT03588975 RECRUITING
A Study of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee
Vericel Corporation n=45
NCT05659082 ENROLLING BY INVITATION
Ventral Capsulotomy for Intractable OCD
Butler Hospital n=50
NCT03299166 COMPLETED
Troriluzole (BHV-4157) in Adult Participants With Obsessive Compulsive Disorder
Biohaven Pharmaceuticals, Inc. n=426
NCT04641143 COMPLETED
Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder
Biohaven Pharmaceuticals, Inc. n=456
NCT04693351 COMPLETED
A Study to Evaluate the Efficacy and Safety of Adjunctive Troriluzole in Obsessive-Compulsive Disorder
Biohaven Pharmaceuticals, Inc. n=589
NCT03348930 COMPLETED
Tolcapone in Obsessive Compulsive Disorder
University of Chicago n=20
NCT01281969 COMPLETED
Intravenous Immunoglobulin for PANDAS
National Institute of Mental Health (NIMH) n=48
NCT01329133 COMPLETED
Deep Brain Stimulation and Obsessive-compulsive Disorder
University Hospital, Bordeaux n=31
NCT01411774 COMPLETED
D-cycloserine Augmentation of Cognitive Behavioral Therapy (CBT) for Pediatric Obsessive-compulsive Disorder (OCD)
University of South Florida n=142
NCT01807403 COMPLETED
Comparison of DBS Targets in Obsessive-compulsive Disorder
Assistance Publique - Hôpitaux de Paris n=8
NCT01178385 COMPLETED
Cognitive-Behavioral Treatment for Anxiety Disorders in Children With Autism Spectrum Disorders
University of South Florida n=45

Full OCD Pipeline

Every trial across Phase 1–4, plus enrollment analytics. Sortable, filterable, exportable.

Unlock with Pro

Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only